Sino Biological has launched an extensive portfolio of recombinant antigens for the 2026-2027 Northern Hemisphere influenza ...

Federal investment in RNA vaccine research has supported nearly three decades of scientific work spanning infectious diseases, cancer, and vaccine development, but recent and proposed funding cuts ...

S Stanley Plotkin recalls a night in 1957, during his pediatrics internship, when a father brought a gravely ill toddler into ...

While current flu shots need to be updated each season, scientists are finding new ways to make vaccine that could last much longer and cover more strains.

Sanofi and Bavarian Nordics are amongst the recipients of contracts that will run for around eight years to help bring new products to market.

Viral mimic systems and other tech platforms could enable local testing of vaccine candidates and antiviral therapies. This ...

Stanford Medicine researchers developed a nasal spray vaccine that protected mice against viruses, bacteria and allergens — a ...

Under the Trump administration, the government has rescinded research funding, changed vaccine recommendations, and refused ...

An international research team has identified a novel HIV antibody that targets the virus at a particularly vulnerable site and overcomes previous limitations of known antibodies. This study, led by ...

Platform-enabled vaccine design unlocks safer, more effective solutions with outer-membrane vesicles (OMVs) emerging as next-generation technology.

CD Bioparticles launches comprehensive OMV-Based Bacterial Vaccines Development services for infectious disease and ...

A challenging public health policy landscape under health secretary Robert F. Kennedy has vaccine makers rethinking developing for the U.S. market.